BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein naturally found in human gastric juice. It has been studied extensively in preclinical models for its ability to accelerate healing across multiple tissue types. BPC-157 is not FDA-approved as a drug and has not completed human clinical trials. Importantly, the FDA has taken action limiting BPC-157 availability under Section 503A compounding regulations for some pharmacies — availability depends on your prescribing clinician and which licensed compounding pharmacy is used. TruVera provides BPC-157 only where permitted and only with a valid prescription from a licensed clinician.

BPC-157 works through several interconnected mechanisms. It promotes angiogenesis — the growth of new blood vessels — by upregulating VEGF, improving blood supply to injured tissue. It modulates nitric oxide signaling pathways that regulate inflammation, vascular tone, and cellular repair. It also interacts with growth hormone receptor signaling locally, amplifying regenerative responses. This combination of mechanisms has been studied in tendon, ligament, muscle, bone, gut lining, and nerve repair models, making BPC-157 one of the more broadly researched peptides in the recovery and healing space.

BPC-157 can be compounded in two main forms depending on your clinical needs. Oral capsules are typically used for gut-focused applications — including leaky gut, IBD-related tissue repair, and intestinal permeability — because the peptide acts locally within the gastrointestinal tract. Subcutaneous injection or localized injection near the site of injury is typically used for musculoskeletal applications such as tendon, ligament, or muscle repair, allowing the peptide to act more directly at the target tissue. Your clinician will specify the appropriate route, dose, and protocol during your consultation.

Response timelines vary by indication and individual. Some patients report early changes within 2–4 weeks; more significant tissue-repair outcomes are generally observed over 4–8 weeks of consistent use. Gut-focused applications may show symptom improvement sooner, while structural musculoskeletal healing — particularly tendons and ligaments — can take the full 6–8 week course or longer depending on injury severity. Your clinician will evaluate your progress at regular check-ins and adjust your protocol as needed.

BPC-157 has been generally well tolerated in preclinical studies. The most commonly noted effects are injection-site reactions (mild redness, swelling, or discomfort) for injectable formulations, and occasional transient gastrointestinal symptoms for oral capsules. It does not carry the immunosuppressive risks associated with corticosteroids. However, it is important to note that long-term human safety data is limited given the absence of completed clinical trials. BPC-157's angiogenic activity also means it is not appropriate for patients with active cancer. Your clinician will conduct a thorough review of your health history before prescribing and will monitor you throughout the program.

Yes. You can pause or cancel at any time through your TruVera patient portal — no phone calls, no cancellation fees. If you have questions about your protocol before canceling, your care team is always available to discuss adjustments or explore whether a different approach might better fit your recovery goals.